Adoptive cellular immunotherapy: NK cells and bone marrow transplantation

C. Y. Koh, L. A. Welniak, W. J. Murphy

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Allogeneic bone marrow transplantation (BMT) has been increasingly used for the treatment of both neoplastic and non-neoplastic disorders. However, serious obstacles currently limit the efficacy and thus more extensive use of BMT. These obstacles include: graft-versus-host disease (GVHD), relapse from the original tumor, and susceptibility of patients to opportunistic infections due to the immunosuppresive effects of the conditioning regimen. Overcoming these obstacles is complicated by dual outcome of existing regimens; attempts to reduce GVHD by depleting T cells from the graft, results in increased rates of tumor relapse and failure of engraftment. On the other hand, efforts to increase graft-versus-tumor (GVT) effects of the transplant also promote GVHD. In this review, the use of natural killer (NK) cells to overcome some of these obstacles of allogeneic BMT is evaluated. Adoptive immunotherapy using NK cells after allogeneic BMT has several potential advantages. First, NK cells can promote hematopoiesis and therefore engraftment by production of hematopoietic growth factors. Second, NK cells have been shown to prevent the incidence and severity of GVHD. This has been shown to be at least partially due to TGF-β, an immunosuppressive cytokine. Third, NK cells have been shown to augment numerous anti-tumor effects in animals after BMT suggesting a vital role of NK cells inmediating GVT effects. Finally, NK cells have been demonstrated to affect B cell recovery and function in mice. Therefore, understanding the mechanisms of beneficial effects of NK cells after BMT may lead to significant increases in the efficacy of this procedure.

Original languageEnglish
Pages (from-to)1201-1210
Number of pages10
JournalHistology and Histopathology
Volume15
Issue number4
Publication statusPublished - 2000

Fingerprint

Adoptive Immunotherapy
Bone Marrow Transplantation
Natural Killer Cells
Graft vs Host Disease
Homologous Transplantation
Transplants
Neoplasms
Recurrence
Opportunistic Infections
Recovery of Function
Hematopoiesis
Immunosuppressive Agents
Intercellular Signaling Peptides and Proteins
B-Lymphocytes
Cytokines
T-Lymphocytes
Incidence

Keywords

  • Allogeneic BMT
  • GVHD
  • GVT
  • NK cells

ASJC Scopus subject areas

  • Cell Biology
  • Anatomy
  • Histology
  • Pathology and Forensic Medicine

Cite this

Adoptive cellular immunotherapy : NK cells and bone marrow transplantation. / Koh, C. Y.; Welniak, L. A.; Murphy, W. J.

In: Histology and Histopathology, Vol. 15, No. 4, 2000, p. 1201-1210.

Research output: Contribution to journalReview article

Koh, C. Y. ; Welniak, L. A. ; Murphy, W. J. / Adoptive cellular immunotherapy : NK cells and bone marrow transplantation. In: Histology and Histopathology. 2000 ; Vol. 15, No. 4. pp. 1201-1210.
@article{f9daf28b54c54ef99cd6fef1a9581867,
title = "Adoptive cellular immunotherapy: NK cells and bone marrow transplantation",
abstract = "Allogeneic bone marrow transplantation (BMT) has been increasingly used for the treatment of both neoplastic and non-neoplastic disorders. However, serious obstacles currently limit the efficacy and thus more extensive use of BMT. These obstacles include: graft-versus-host disease (GVHD), relapse from the original tumor, and susceptibility of patients to opportunistic infections due to the immunosuppresive effects of the conditioning regimen. Overcoming these obstacles is complicated by dual outcome of existing regimens; attempts to reduce GVHD by depleting T cells from the graft, results in increased rates of tumor relapse and failure of engraftment. On the other hand, efforts to increase graft-versus-tumor (GVT) effects of the transplant also promote GVHD. In this review, the use of natural killer (NK) cells to overcome some of these obstacles of allogeneic BMT is evaluated. Adoptive immunotherapy using NK cells after allogeneic BMT has several potential advantages. First, NK cells can promote hematopoiesis and therefore engraftment by production of hematopoietic growth factors. Second, NK cells have been shown to prevent the incidence and severity of GVHD. This has been shown to be at least partially due to TGF-β, an immunosuppressive cytokine. Third, NK cells have been shown to augment numerous anti-tumor effects in animals after BMT suggesting a vital role of NK cells inmediating GVT effects. Finally, NK cells have been demonstrated to affect B cell recovery and function in mice. Therefore, understanding the mechanisms of beneficial effects of NK cells after BMT may lead to significant increases in the efficacy of this procedure.",
keywords = "Allogeneic BMT, GVHD, GVT, NK cells",
author = "Koh, {C. Y.} and Welniak, {L. A.} and Murphy, {W. J.}",
year = "2000",
language = "English",
volume = "15",
pages = "1201--1210",
journal = "Histology and Histopathology",
issn = "0213-3911",
publisher = "Histology and Histopathology",
number = "4",

}

TY - JOUR

T1 - Adoptive cellular immunotherapy

T2 - NK cells and bone marrow transplantation

AU - Koh, C. Y.

AU - Welniak, L. A.

AU - Murphy, W. J.

PY - 2000

Y1 - 2000

N2 - Allogeneic bone marrow transplantation (BMT) has been increasingly used for the treatment of both neoplastic and non-neoplastic disorders. However, serious obstacles currently limit the efficacy and thus more extensive use of BMT. These obstacles include: graft-versus-host disease (GVHD), relapse from the original tumor, and susceptibility of patients to opportunistic infections due to the immunosuppresive effects of the conditioning regimen. Overcoming these obstacles is complicated by dual outcome of existing regimens; attempts to reduce GVHD by depleting T cells from the graft, results in increased rates of tumor relapse and failure of engraftment. On the other hand, efforts to increase graft-versus-tumor (GVT) effects of the transplant also promote GVHD. In this review, the use of natural killer (NK) cells to overcome some of these obstacles of allogeneic BMT is evaluated. Adoptive immunotherapy using NK cells after allogeneic BMT has several potential advantages. First, NK cells can promote hematopoiesis and therefore engraftment by production of hematopoietic growth factors. Second, NK cells have been shown to prevent the incidence and severity of GVHD. This has been shown to be at least partially due to TGF-β, an immunosuppressive cytokine. Third, NK cells have been shown to augment numerous anti-tumor effects in animals after BMT suggesting a vital role of NK cells inmediating GVT effects. Finally, NK cells have been demonstrated to affect B cell recovery and function in mice. Therefore, understanding the mechanisms of beneficial effects of NK cells after BMT may lead to significant increases in the efficacy of this procedure.

AB - Allogeneic bone marrow transplantation (BMT) has been increasingly used for the treatment of both neoplastic and non-neoplastic disorders. However, serious obstacles currently limit the efficacy and thus more extensive use of BMT. These obstacles include: graft-versus-host disease (GVHD), relapse from the original tumor, and susceptibility of patients to opportunistic infections due to the immunosuppresive effects of the conditioning regimen. Overcoming these obstacles is complicated by dual outcome of existing regimens; attempts to reduce GVHD by depleting T cells from the graft, results in increased rates of tumor relapse and failure of engraftment. On the other hand, efforts to increase graft-versus-tumor (GVT) effects of the transplant also promote GVHD. In this review, the use of natural killer (NK) cells to overcome some of these obstacles of allogeneic BMT is evaluated. Adoptive immunotherapy using NK cells after allogeneic BMT has several potential advantages. First, NK cells can promote hematopoiesis and therefore engraftment by production of hematopoietic growth factors. Second, NK cells have been shown to prevent the incidence and severity of GVHD. This has been shown to be at least partially due to TGF-β, an immunosuppressive cytokine. Third, NK cells have been shown to augment numerous anti-tumor effects in animals after BMT suggesting a vital role of NK cells inmediating GVT effects. Finally, NK cells have been demonstrated to affect B cell recovery and function in mice. Therefore, understanding the mechanisms of beneficial effects of NK cells after BMT may lead to significant increases in the efficacy of this procedure.

KW - Allogeneic BMT

KW - GVHD

KW - GVT

KW - NK cells

UR - http://www.scopus.com/inward/record.url?scp=0033819721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033819721&partnerID=8YFLogxK

M3 - Review article

C2 - 11005245

AN - SCOPUS:0033819721

VL - 15

SP - 1201

EP - 1210

JO - Histology and Histopathology

JF - Histology and Histopathology

SN - 0213-3911

IS - 4

ER -